Generic Name and Formulations:
Acrivastine 8mg, pseudoephedrine HCl 60mg; caps.
- Blood Biomarkers Add Value to COPD Mortality Predictive Model
- Performing Two 6MWTs in Pulmonary Hypertension Minimizes "Learning Effect"
- Prognostic Value of 6MWT in Pulmonary Arterial Hypertension
Indications for SEMPREX-D:
Seasonal allergic rhinitis symptoms.
1 cap every 4–6 hours, max 4/day.
Severe hypertension or coronary artery disease. During or within 14 days of MAOIs.
Hypertension. Diabetes. Ischemic heart disease. Increased intraocular pressure. Hyperthyroidism. GI or GU obstruction. Elderly. Pregnancy (Cat.B). Renal impairment (CrCl ≤48mL/minute), nursing mothers: not recommended.
Hypertensive crisis with MAOIs. β-blockers may increase the pressor effects of sympathomimetics. Alcohol, other CNS depressants potentiated. Antagonizes antihypertensives.
Antihistamine + sympathomimetic.
Somnolence, dry mouth, nervousness, insomnia, ephedrine-like reactions (tachycardia, palpitations, headache, dizziness, nausea).